Low energy internal cardioversion of atrial fibrillation resistant to transthoracic shocks

S Mark Sopher, Francis D Murgatroyd, Alistair K B Slade, Ivan Blankoff, Edward Rowland, David E Ward, A John Camm

Abstract

Objective—To investigate the efficacy of internal cardioversion using low energy shocks delivered with a biatral electrode configuration in chronic atrial fibrillation resistant to transthoracic shocks.

Methods—Low energy internal cardioversion was attempted in 11 patients who had been in atrial fibrillation for 233 (SD 193) days and had failed to cardiovert with transthoracic shocks of 360 J in both apex-base and anterior-posterior positions. Synchronised biphasic shocks of up to 400 V (< 6 J) were delivered, usually with intravenous sedation only, between high surface area electrodes in the right atrium and the left atrium (coronary sinus in nine, left pulmonary artery in one, left atrium via patent foramen ovale in one).

Results—Sinus rhythm was restored in 8/11 patients. The mean leading edge voltage of successful shocks was 363 (46) V [4.9 (1-3) J]. Higher energy shocks induced transient bradycardia (time to first R wave 1955 (218) ms). No proarrhythmia or other acute complications were observed.

Conclusions—Low energy internal cardioversion of atrial fibrillation can restore sinus rhythm in patients in whom conventional transthoracic shocks have failed.

(Heart 1996;75:635–638)

Keywords: arrhythmia; atrial fibrillation; electric countershock

Transcutaneous direct current capacitor discharge has been used for more than 30 years to terminate persistent atrial fibrillation. The restoration of sinus rhythm yields haemodynamic and symptomatic benefits and is assumed to reduce the risk of thromboembolic complications associated with atrial fibrillation. However, external cardioversion using energies of up to 360 J fails to restore sinus rhythm in a proportion of patients. Animal studies have suggested that defibrillation efficiency can be greatly increased using biphasic shocks delivered between high surface area electrodes in an arrangement that surrounds both atria, especially the right atrium-coronary sinus configuration. In patients, this technique is able to terminate acute atrial fibrillation with energies of 1-5 J. This confirms that the "biatral" electrode configuration is a highly efficient means of electrical field delivery, and suggests that it might succeed in cases where conventional methods have failed.

We therefore attempted to terminate atrial fibrillation using low energy shocks delivered between transvenous electrodes in a biatral configuration in a series of patients who had previously failed conventional transthoracic cardioversion.

Methods

Patients

Consultants were invited to refer adult patients with persistent (more than two weeks) atrial fibrillation in whom transthoracic shocks of 360 V, delivered between paddles in both apex-base and anteroposterior positions, had failed to restore sinus rhythm, even transiently. Patients were excluded if they had a history of stroke or peripheral embolism, or reversible cause of atrial fibrillation. All patients were studied within three months of undergoing the transthoracic shocks and a transthoracic echocardiogram.

Study protocol

Antiarrhythmic medication was at the discretion of the referring cardiologist, and was not interrupted for the procedure. Anticoagulation with warfarin was reduced (INR < 2:0) before the invasive procedure and subsequently restarted according to our usual practice. Intravenous sedation (midazolam and diamorphine) was given before the start of the procedure, with additional doses as required.

The procedure has been described in detail in a previous report. Defibrillation shocks were delivered between two identical catheters (Electro Catheter Inc) each with an electrode of length 6 cm and surface area 2-83 cm² which were positioned transvenously in the anterolateral right atrium and the coronary sinus (figure). A standard pacing catheter was positioned at the right ventricular apex in case of profound bradycardia following shocks. A custom made external defibrillator (XAD, InControl Inc) delivered R wave synchronised biphasic shocks with a leading edge voltage programmable
between 10 and 400 V. To minimise the risk of ventricular proarhythmia the device was programmed to deliver shocks only after RR intervals above 500 ms (see Discussion). After a test shock of 10 V to verify correct R wave synchronisation, a series of shocks at > 30 s intervals was given increasing from 20 V in 40 V steps until atrial fibrillation was terminated or a 400 V shock was delivered. If a 400 V shock failed to terminate atrial fibrillation the catheter positions were checked on fluoroscopy and corrected if displacement had occurred. Two further shocks of 400 V were then delivered. The surface electrocardiogram was recorded continuously during the procedure.

### Results

**PATIENTS**

Eleven patients entered the study (table 1). The mean duration of atrial fibrillation at the time of the procedure was 233 (SD 193) days. Four patients had evidence of underlying cardiac disease. Six patients had been taking an antiarrhythmic drug at the time of the attempt at external cardioversion but this had been discontinued in three before referral for internal cardioversion.

**OUTCOMES**

There were four deviations from protocol. In two early patients, the procedure was performed under general anaesthesia in anticipation of the need for high energy internal cardioversion. In two patients, the coronary sinus could not be cannulated: the left atrial electrode was positioned in the left main pulmonary artery in one and in the left atrium itself (through a patent foramen ovale) in the other.

Successful cardioversion (defined as the immediate return of sinus rhythm following a shock) was achieved in eight patients. The mean (SD) leading edge voltage of successful shocks was 363 (46) V (range, 260–400 V) and the mean energy was 4·9 (1·2) J (range, 2·5–6·2 J).

Three patients failed to cardiovert despite three shocks of 400 V.

**COMPLICATIONS**

No ventricular arrhythmia was seen acutely following a shock. Bradycardia was seen following higher energy shocks whether or not sinus rhythm was restored. The mean of the longest delay from any shock to the first R wave in each patient was 1955 (218) ms (range, 400–2640 ms). However, no patient required back ventricular pacing as this bradycardia was transient.

Two patients experienced possible late complications of the technique of internal cardioversion or of the reduction in the level of their anticoagulation. Patient 2 presented locally five days after the successful cardioversion with a four day history of an increasingly cold and numb right lower limb. He had reverted to atrial fibrillation 24 hours after the procedure. An embolus to the right popliteal artery was confirmed and successfully treated. Patient 9 collapsed out of hospital eight hours after the unsuccessful but apparently uncomplicated procedure. Cardiopulmonary resuscitation was only instituted around 15 minutes later when ventricular fibrillation was recorded. Following a prolonged resuscitation he suffered severe hypoxic cerebral damage and died after three weeks. No cerebral infarct or source of embolus was identified. There had been no history suggestive of ischaemic heart disease and there was no clear evidence of acute myocardial infarction. However, necropsy examination revealed coronary atheroma particularly involv-

### Table 1  Clinical details of the patients

<table>
<thead>
<tr>
<th>No</th>
<th>Age (years)</th>
<th>Sex</th>
<th>LA diameter (mm)</th>
<th>AF duration (days)</th>
<th>Known CVS disease</th>
<th>AA drugs (at ext cardioversion)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>59</td>
<td>F</td>
<td>56</td>
<td>420</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>58</td>
<td>M</td>
<td>43</td>
<td>270</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>46</td>
<td>M</td>
<td>37</td>
<td>210</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>48</td>
<td>M</td>
<td>39</td>
<td>180</td>
<td></td>
<td>Amiodarone</td>
</tr>
<tr>
<td>5</td>
<td>58</td>
<td>M</td>
<td>50</td>
<td>295</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>55</td>
<td>M</td>
<td>47</td>
<td>90</td>
<td>DCM (alcohol)</td>
<td>Amiodarone</td>
</tr>
<tr>
<td>7</td>
<td>30</td>
<td>F</td>
<td>56</td>
<td>50</td>
<td>HOCM</td>
<td>Dofetilide</td>
</tr>
<tr>
<td>8</td>
<td>23</td>
<td>M</td>
<td>41</td>
<td>14</td>
<td>DCM (idiopathic)</td>
<td>Quinidine</td>
</tr>
<tr>
<td>9</td>
<td>43</td>
<td>M</td>
<td>44</td>
<td>730</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>57</td>
<td>M</td>
<td>52</td>
<td>120</td>
<td></td>
<td>Atenolol</td>
</tr>
<tr>
<td>11</td>
<td>69</td>
<td>F</td>
<td>49</td>
<td>180</td>
<td></td>
<td>IHD</td>
</tr>
</tbody>
</table>

M, male; F, female; AF duration, time in continuous atrial fibrillation before internal cardioversion; CVS disease, evident cardiovascular disease (ACM, alcoholic cardiomyopathy; DCM, idiopathic dilated cardiomyopathy; HOCM, hypertrophic cardiomyopathy; HHD, ischaemic heart disease); AA drugs, antiarrhythmic medication at time of failed transthoracic cardioversion (ext cardioversion).

### Table 2  Details of internal cardioversion procedure

<table>
<thead>
<tr>
<th>No</th>
<th>Electrode configuration</th>
<th>Successful leading edge voltage (V)</th>
<th>Successful energy (J)</th>
<th>Impedance (Ohms) (at success or 400 V)</th>
<th>AA drugs</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>RA:CS</td>
<td>400</td>
<td>6·2</td>
<td>45</td>
<td>Amiodarone</td>
</tr>
<tr>
<td>2</td>
<td>RA:CS</td>
<td>340</td>
<td>4·3</td>
<td>54</td>
<td>Amiodarone</td>
</tr>
<tr>
<td>3</td>
<td>RA:CS</td>
<td>360</td>
<td>4·6</td>
<td>64</td>
<td>Amiodarone</td>
</tr>
<tr>
<td>4</td>
<td>RA:CS</td>
<td>400</td>
<td>6·0</td>
<td>53</td>
<td>Amiodarone</td>
</tr>
<tr>
<td>5</td>
<td>RA:CS</td>
<td>400</td>
<td>5·4</td>
<td>79</td>
<td>Amiodarone</td>
</tr>
<tr>
<td>6</td>
<td>RA:LA (PFO)</td>
<td>400</td>
<td>6·2</td>
<td>44</td>
<td>Dofetilide</td>
</tr>
<tr>
<td>7</td>
<td>RA:CS</td>
<td>260</td>
<td>2·5</td>
<td>55</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>RA:CS</td>
<td>400</td>
<td>4·1</td>
<td>68</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>RA:CS</td>
<td></td>
<td></td>
<td>68</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>RA:CS</td>
<td></td>
<td></td>
<td>64</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>RA:LA:PA</td>
<td></td>
<td></td>
<td>56</td>
<td></td>
</tr>
</tbody>
</table>

RA, right atrium; CS, coronary sinus; LA (via PFO), left atrium through patent foramen ovale; LPA, left pulmonary artery; AA drugs, antiarrhythmic medication at time of procedure.
ing the left coronary artery and the suggestion of a small recent ventricular septal infarct. The relation, if any, of this to the procedure is unclear.

Discussion

CARDIOVERSION OF ATRIAL FIBRILLATION

Atrial fibrillation is the commonest sustained cardiac arrhythmia and accounts for most hospital admissions and days in hospital. It frequently causes disabling symptoms and haemodynamic impairment and is an important treatable cause of stroke. Restoration of sinus rhythm results in improved left ventricular function and functional capacity even in patients with a previously controlled ventricular rate. Electrical cardioversion is more effective than using antiarrhythmic drugs and has become the standard technique for cardioversion of chronic atrial fibrillation. However, the technique is not uniformly effective. The age of the patient and the arrhythmia duration have been shown to be independent predictors of failure, while other factors such as left atrial diameter and rheumatic aetiology may also be used to indicate a likelihood of failure.

Patients in whom transthoracic cardioversion fails are generally accepted as being in permanent atrial fibrillation. However, other methods can be used to obtain the benefits of sinus rhythm. Antiarrhythmic drugs alone are rarely effective in cardioverting chronic atrial fibrillation resistant to transthoracic shock, but an increased success rate can be achieved when cardioversion is repeated after loading with amiodarone. In contrast, class Ic antiarrhythmic drugs may increase the atrial defibrillation threshold. Surgical options such as the maze operation may restore and maintain sinus rhythm but are major procedures with significant morbidity. Simpler operations which do not restore mechanical function of the atria, such as left atrial isolation and the corridor procedure, may not achieve the haemodynamic benefit of normal sinus rhythm or reduce the thromboembolic risk associated with atrial fibrillation.

INTERNAL CARDIOVERSION

Another approach is to try to increase the efficacy of electrical cardioversion by using an internal electrode arrangement that increases the potential gradient achieved within atrial tissue. Low energy intracardiac shocks have been known to terminate ventricular fibrillation refractory to multiple transthoracic shocks, but have only recently been investigated in atrial fibrillation. Capacitor discharge between the proximal pole of a pacing catheter in the right atrium and a backplate has been described by Lévy et al. A higher success rate was obtained with this method than with repeated external cardioversion (91% vs 67%) in a randomised trial of patients with "resistant" atrial fibrillation after pretreatment with amiodarone. However this technique uses 200–300 J intracavitary shocks, which are known to cause arcing with gas bubble formation, which can result in barotrauma. This may account for severe complications recently reported, and may be responsible for reluctance to use the technique.

In theory, the most efficient electrode configuration for atrial defibrillation is in proximity to the atria and providing a field which embraces both atria. A systematic investigation in a sheep model of acute atrial fibrillation found that a defibrillation threshold of around 1 J could be obtained with a biphasic shock waveform and a biatrial high surface area electrode configuration, especially one using the coronary sinus for the left sided electrode. The efficacy of this method has been confirmed in patients with induced and spontaneous paroxysmal atrial fibrillation. The atrial defibrillation threshold was generally 1–5 J. General anaesthesia is therefore unnecessary. The method has been effective in two patients in whom morbid obesity might account for failure of transthoracic cardioversion. However, the technique has not previously been applied systematically to a series of patients with persistent atrial fibrillation refractory to conventional transthoracic shocks.

In our study, biphasic biatrial shocks terminated atrial fibrillation in eight out of 11 patients who had previously failed external cardioversion. No formal attempt was made to select patients with a high likelihood of success. However, as in previous studies, patients were most likely to be referred for cardioversion if it was perceived that there was a reasonable chance of success, or a particular reason for the patient to benefit from sinus rhythm. Thus the patients were young (23 to 69 years) compared to the population with chronic atrial fibrillation; none had significant valvar heart disease; and while most had left atrial dilatation, this did not exceed 5–6 cm. None of the patients studied were obese or had chest hypexpansion which might have affected the transthoracic impedance. Those that were taking antiarrhythmic drug treatment had previously failed external cardioversion while on the same treatment.

With a limited number of subjects, it is not possible to draw firm conclusions about why the technique failed in three patients. One (No 10) was the first patient with "resistant" atrial fibrillation to undergo the technique, and only one attempt was made at maximum output (400 V). In patient 11, the left sided electrode was situated in the left main pulmonary artery as the coronary sinus could not be cannulated. This position is associated with a higher defibrillation threshold in the sheep model. Patient 9 had been in atrial fibrillation for considerably longer than others in the series. In all cases, the energy delivered (up to 6·2 J) was limited by the maximum output (400 V) of the defibrillator used. It is not known whether a higher output would have further increased the likelihood of success.

The study did not address the issue of maintenance of sinus rhythm following successful cardioversion and there was no policy regarding the use of antiarrhythmic drugs. In most series, the risk of atrial fibrillation recurrence within a year of cardioversion is approximately 50%, and this is likely to be higher in patients with "resistant" atrial fibrillation. However,
antiarrhythmic treatment can considerably reduce the risk of atrial fibrillation recurrence and should therefore be considered routinely for patients undergoing this technique.

SAFETY
The risk that biaxial shocks may induce ventricular tachyarrhythmias has been systemati-
cally evaluated in sheep.26 Such proarrhythmia does not occur if shocks are synchronised to the R wave and delivered following an RR interval of more than 300 ms. To allow a margin of safety, we programmed the defibrillator to a minimum interval of 500 ms. In a rapidly growing worldwide experience, no proarrhythmia has been seen with correctly synchronised shocks delivered in patients using a biaxial configuration.25

Intracavitary shocks delivered from point electrodes can cause microscopic changes of subendocardial necrosis in the right atrium, and serious complications have been reported for shocks of more than 100 J delivered within the coronary sinus in animals.26,27 and man.30 However, no injury has been reported with shocks of 30 J in current ventricular defibrillation systems employing electrodes in the coro-
nary sinus.31,32 This is presumably because, with high surface area electrodes, defibrillation relies solely on the electrical field generated and not on barotrauma.

There were no acute arthritic or mechan-
ical complications in the present study. However marked transient bradycardia was common following shocks above 4 J. Pacing was not necessary, but it would seem a prudent precaution to have this facility in patients with longstanding atrial fibrillation whose sinus node function is undetermined. Precautions to reduce the risks of excessive bleeding or thrombo-
embolic complications are also required when performing an invasive procedure in patients anticoagulated for atrial fibrillation.

CONCLUSIONS
Sinus rhythm can be restored in a proportion of patients with atrial fibrillation in whom conven-
tional transesophageal shocks have failed, using biphasic shocks delivered between the right atrium and the coronary sinus. The energy required is very low, and general anaesthesia is not required. Low energy internal cardioversion should be considered in patients for whom conven-
tional methods have failed or are impossible. The role of this new technique should be formally explored in large scale studies.

SMS is supported by a Junior Research Fellowship of the British Heart Foundation. This study was funded in part by grants from the British Heart Foundation and from Incontrol, Inc.

1 Lown B, Amassian RS, Neuman J. New method for termi-
nating cardiac arrhythmias—use of synchronized cap-
3 Keaney D, Boyd E, Anderson D, et al. Comparison of biphasic and monophasic waveforms in epicardial atrial fibrilla-
19 Baker BM, Botteron GW, Smith JM. Low-energy internal cardioversion for atrial fibrillation resistant to external car-
21 Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for mainte-
22 Crnja HJ, Van Gelder IC, Van Gilst WH, Hillege H, Goulielqu ATM, Lie KI. Serial antiarhythmic drug treat-
ment to maintain sinus rhythm after electrical cardiover-
23 Ayers GM, Alferness CA, Ilina M, et al. Ventricular proar-
rhythm effects of ventricular cycle length and shock strength in a sheep model of transvenous atrial defibrilla-
24 Murgatroyd FD, Johnson ES, Cooper RA, et al. Safety of low energy transvenous atrial defibrillation—prelimi-
25 Durbin DN, Tobler HG, Ferrier J, Gornick CC, Benson DWJ, Benditt DG. Intracavitary electrode catheter cardio-
27 Colotroto F, Bardy GH, Reichenbach D, et al. Catheter-mediated electrical ablation of the posterior septum via the coronary sinus: electrophysiological and histologic observa-
31 Bardy GH, Allen MD, Mehrs R, et al. Transvenous defibril-